Acadia Pharmaceuticals
ACAD
246 hedge funds and large institutions have $6.51B invested in Acadia Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 88 increasing their positions, 83 reducing their positions, and 59 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
2.04% more ownership
Funds ownership: 97.22% → 99.26% (+2%)
6% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 83
2% more capital invested
Capital invested by funds: $6.41B → $6.51B (+$106M)
1% less call options, than puts
Call options by funds: $39.8M | Put options by funds: $40.3M
10% less funds holding
Funds holding: 273 → 246 (-27)
41% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 59
Top Buyers
| 1 |
HM
HealthCor Management
New York
|
+$91.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$61.4M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$55.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$44.4M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$43.3M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$58.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$39.2M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$33.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.7M |
| 5 |
Millennium Management
New York
|
-$28M |
ACAD Hedge Fund Activity: Q1 2020 in Review
246 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2020, worth a combined $6.51B — up 1.7% from $6.41B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of ACAD and 35 opened new positions — a net loss of 24 holders — while 83 trimmed existing stakes and 88 added.
The largest buyer was HealthCor Management, opening a new position worth an estimated $91.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $58.2M.
- 246 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2020, down from 273 in Q4 2019.
- Funds reported $6.51B of Acadia Pharmaceuticals stock for Q1 2020, up 1.7% quarter-over-quarter.
- 35 funds opened new Acadia Pharmaceuticals positions in Q1 2020 and 59 closed out, a net change of -24 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2020 was HealthCor Management, an estimated $91.9M added.
- The largest Acadia Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $58.2M sold.
Based on aggregated 13F filings for Q1 2020.